{"transactions":[{"id":4634682,"issuer":{"id":183937,"kind":"organization","name":"ADARx Pharmaceuticals, Inc.","symbol":"ADRX"},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Preferred Stock","published_at":"2026-09-30T21:29:36.000Z","date":"2026-09-28","kind":"exercise","planned":false,"acquired":false,"shares":256448,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP\") is the general partner of OIP II. OrbiMed Advisors Israel II Limited (\"Advisors Israel\") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors Israel may be deemed to have voting power and investment power over the securities held by OIP II and as a result, may be deemed to have beneficial ownership over such securities. Advisors Israel exercises this investment and voting power through a management committee comprised of Carl L. Gordon, David P. Bonita, and the Reporting Person, each of whom disclaims beneficial ownership of the shares held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, Israel GP, and Advisors Israel disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":256448},"source":{"system":"sec-edgar","filing":"0000947871-26-000912","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787126000912/ownership.xml","form_type":"4"}},{"id":4634681,"issuer":{"id":183937,"kind":"organization","name":"ADARx Pharmaceuticals, Inc.","symbol":"ADRX"},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2026-09-30T21:29:36.000Z","date":"2026-09-28","kind":"exercise","planned":false,"acquired":false,"shares":513067,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP\") is the general partner of OIP II. OrbiMed Advisors Israel II Limited (\"Advisors Israel\") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors Israel may be deemed to have voting power and investment power over the securities held by OIP II and as a result, may be deemed to have beneficial ownership over such securities. Advisors Israel exercises this investment and voting power through a management committee comprised of Carl L. Gordon, David P. Bonita, and the Reporting Person, each of whom disclaims beneficial ownership of the shares held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, Israel GP, and Advisors Israel disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":513067},"source":{"system":"sec-edgar","filing":"0000947871-26-000912","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787126000912/ownership.xml","form_type":"4"}},{"id":4634680,"issuer":{"id":183937,"kind":"organization","name":"ADARx Pharmaceuticals, Inc.","symbol":"ADRX"},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-09-30T21:29:36.000Z","date":"2026-09-28","kind":"exercise","planned":false,"acquired":false,"shares":1333975,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP\") is the general partner of OIP II. OrbiMed Advisors Israel II Limited (\"Advisors Israel\") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors Israel may be deemed to have voting power and investment power over the securities held by OIP II and as a result, may be deemed to have beneficial ownership over such securities. Advisors Israel exercises this investment and voting power through a management committee comprised of Carl L. Gordon, David P. Bonita, and the Reporting Person, each of whom disclaims beneficial ownership of the shares held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, Israel GP, and Advisors Israel disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1333975},"source":{"system":"sec-edgar","filing":"0000947871-26-000912","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787126000912/ownership.xml","form_type":"4"}},{"id":4634679,"issuer":{"id":183937,"kind":"organization","name":"ADARx Pharmaceuticals, Inc.","symbol":"ADRX"},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2026-09-30T21:29:36.000Z","date":"2026-09-28","kind":"exercise","planned":false,"acquired":false,"shares":7127019,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP\") is the general partner of OIP II. OrbiMed Advisors Israel II Limited (\"Advisors Israel\") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors Israel may be deemed to have voting power and investment power over the securities held by OIP II and as a result, may be deemed to have beneficial ownership over such securities. Advisors Israel exercises this investment and voting power through a management committee comprised of Carl L. Gordon, David P. Bonita, and the Reporting Person, each of whom disclaims beneficial ownership of the shares held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, Israel GP, and Advisors Israel disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7127019},"source":{"system":"sec-edgar","filing":"0000947871-26-000912","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787126000912/ownership.xml","form_type":"4"}},{"id":4634678,"issuer":{"id":183937,"kind":"organization","name":"ADARx Pharmaceuticals, Inc.","symbol":"ADRX"},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-30T21:29:36.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":61516,"price":17,"value":1045772.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP\") is the general partner of OIP II. OrbiMed Advisors Israel II Limited (\"Advisors Israel\") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors Israel may be deemed to have voting power and investment power over the securities held by OIP II and as a result, may be deemed to have beneficial ownership over such securities. Advisors Israel exercises this investment and voting power through a management committee comprised of Carl L. Gordon, David P. Bonita, and the Reporting Person, each of whom disclaims beneficial ownership of the shares held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, Israel GP, and Advisors Israel disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":9292025,"source":{"system":"sec-edgar","filing":"0000947871-26-000912","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787126000912/ownership.xml","form_type":"4"}},{"id":4634677,"issuer":{"id":183937,"kind":"organization","name":"ADARx Pharmaceuticals, Inc.","symbol":"ADRX"},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-30T21:29:36.000Z","date":"2026-09-28","kind":"exercise","planned":false,"acquired":true,"shares":256448,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP\") is the general partner of OIP II. OrbiMed Advisors Israel II Limited (\"Advisors Israel\") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors Israel may be deemed to have voting power and investment power over the securities held by OIP II and as a result, may be deemed to have beneficial ownership over such securities. Advisors Israel exercises this investment and voting power through a management committee comprised of Carl L. Gordon, David P. Bonita, and the Reporting Person, each of whom disclaims beneficial ownership of the shares held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, Israel GP, and Advisors Israel disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":9230509,"source":{"system":"sec-edgar","filing":"0000947871-26-000912","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787126000912/ownership.xml","form_type":"4"}},{"id":4634676,"issuer":{"id":183937,"kind":"organization","name":"ADARx Pharmaceuticals, Inc.","symbol":"ADRX"},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-30T21:29:36.000Z","date":"2026-09-28","kind":"exercise","planned":false,"acquired":true,"shares":513067,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP\") is the general partner of OIP II. OrbiMed Advisors Israel II Limited (\"Advisors Israel\") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors Israel may be deemed to have voting power and investment power over the securities held by OIP II and as a result, may be deemed to have beneficial ownership over such securities. Advisors Israel exercises this investment and voting power through a management committee comprised of Carl L. Gordon, David P. Bonita, and the Reporting Person, each of whom disclaims beneficial ownership of the shares held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, Israel GP, and Advisors Israel disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":8974061,"source":{"system":"sec-edgar","filing":"0000947871-26-000912","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787126000912/ownership.xml","form_type":"4"}},{"id":4634675,"issuer":{"id":183937,"kind":"organization","name":"ADARx Pharmaceuticals, Inc.","symbol":"ADRX"},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-30T21:29:36.000Z","date":"2026-09-28","kind":"exercise","planned":false,"acquired":true,"shares":1333975,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP\") is the general partner of OIP II. OrbiMed Advisors Israel II Limited (\"Advisors Israel\") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors Israel may be deemed to have voting power and investment power over the securities held by OIP II and as a result, may be deemed to have beneficial ownership over such securities. Advisors Israel exercises this investment and voting power through a management committee comprised of Carl L. Gordon, David P. Bonita, and the Reporting Person, each of whom disclaims beneficial ownership of the shares held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, Israel GP, and Advisors Israel disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":8460994,"source":{"system":"sec-edgar","filing":"0000947871-26-000912","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787126000912/ownership.xml","form_type":"4"}},{"id":4634674,"issuer":{"id":183937,"kind":"organization","name":"ADARx Pharmaceuticals, Inc.","symbol":"ADRX"},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-30T21:29:36.000Z","date":"2026-09-28","kind":"exercise","planned":false,"acquired":true,"shares":7127019,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP\") is the general partner of OIP II. OrbiMed Advisors Israel II Limited (\"Advisors Israel\") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors Israel may be deemed to have voting power and investment power over the securities held by OIP II and as a result, may be deemed to have beneficial ownership over such securities. Advisors Israel exercises this investment and voting power through a management committee comprised of Carl L. Gordon, David P. Bonita, and the Reporting Person, each of whom disclaims beneficial ownership of the shares held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, Israel GP, and Advisors Israel disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":7127019,"source":{"system":"sec-edgar","filing":"0000947871-26-000912","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787126000912/ownership.xml","form_type":"4"}},{"id":690810,"issuer":{"id":4564,"kind":"organization","name":"Braveheart Bio, Inc."},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2026-08-11T21:31:57.000Z","date":"2026-08-07","kind":"exercise","planned":false,"acquired":false,"shares":40000000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-4.38 basis upon the closing of the Issuer's initial public offering on August 7, 2026 without payment of consideration. The Series A Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-4.38 basis upon the closing of the Issuer's initial public offering on August 7, 2026 without payment of consideration. The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-4.38 basis upon the closing of the Issuer's initial public offering on August 7, 2026 without payment of consideration. The Series A Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\"). OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IX. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":9132420},"source":{"system":"sec-edgar","filing":"0000947871-26-000783","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787126000783/ownership.xml","form_type":"4"}},{"id":690809,"issuer":{"id":4564,"kind":"organization","name":"Braveheart Bio, Inc."},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T21:31:57.000Z","date":"2026-08-07","kind":"purchase","planned":false,"acquired":true,"shares":273333,"price":18,"value":4919994.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by Genesis and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":273333,"source":{"system":"sec-edgar","filing":"0000947871-26-000783","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787126000783/ownership.xml","form_type":"4"}},{"id":690808,"issuer":{"id":4564,"kind":"organization","name":"Braveheart Bio, Inc."},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T21:31:57.000Z","date":"2026-08-07","kind":"purchase","planned":false,"acquired":true,"shares":1666667,"price":18,"value":30000006.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\"). OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IX. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":11901826,"source":{"system":"sec-edgar","filing":"0000947871-26-000783","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787126000783/ownership.xml","form_type":"4"}},{"id":690807,"issuer":{"id":4564,"kind":"organization","name":"Braveheart Bio, Inc."},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T21:31:57.000Z","date":"2026-08-07","kind":"exercise","planned":false,"acquired":true,"shares":9132420,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-4.38 basis upon the closing of the Issuer's initial public offering on August 7, 2026 without payment of consideration. The Series A Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\"). OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IX. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":10235159,"source":{"system":"sec-edgar","filing":"0000947871-26-000783","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787126000783/ownership.xml","form_type":"4"}},{"id":693085,"issuer":{"id":4564,"kind":"organization","name":"Braveheart Bio, Inc."},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-07T20:31:24.000Z","date":"2026-08-05","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option will vest in full upon the earlier of (i) August 5, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to an agreement with OrbiMed Advisors LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof to OrbiMed Advisors LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments IX, LP."}],"balance_after":30000,"derivative":{"exercise_price":18,"expiration_date":"2036-08-04","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001470831-26-000802","document":"wk-form4_1786134681.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000147083126000802/wk-form4_1786134681.xml","form_type":"4"}},{"id":741982,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T00:00:03.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":17096,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in full upon the earlier of (i) June 9, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to an agreement with OrbiMed Advisors LLC, OrbiMed Capital GP VIII LLC, OrbiMed Israel GP II, L.P., and OrbiMed Advisors Israel II Limited, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC, OrbiMed Capital GP VIII LLC, OrbiMed Israel GP II, L.P., and OrbiMed Advisors Israel II Limited, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VIII, LP and OrbiMed Israel Partners II, L.P."}],"balance_after":17096,"derivative":{"exercise_price":6.69,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":17096},"source":{"system":"sec-edgar","filing":"0001193125-26-268164","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022626/000119312526268164/ownership.xml","form_type":"4"}},{"id":1113805,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:17:31.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":17096,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest upon the earlier of (i) June 10, 2026 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to an agreement with OrbiMed Advisors LLC, OrbiMed Capital GP VIII LLC, OrbiMed Israel GP II, L.P., and OrbiMed Advisors Israel II Limited, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC, OrbiMed Capital GP VIII LLC, OrbiMed Israel GP II, L.P., and OrbiMed Advisors Israel II Limited, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VIII, LP and OrbiMed Israel Partners II, L.P."}],"balance_after":17096,"derivative":{"exercise_price":11.59,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":17096},"source":{"system":"sec-edgar","filing":"0000950170-25-085371","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022626/000095017025085371/ownership.xml","form_type":"4"}},{"id":1385002,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B redeemable convertible preferred stock","published_at":"2024-10-17T20:19:30.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":789833,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, Advisors II, Israel GP, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, Advisors II, Israel GP, OrbiMed Advisors, or GP VIII is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":789833},"source":{"system":"sec-edgar","filing":"0000947871-24-000807","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2022626/000094787124000807/ownership.xml","form_type":"4"}},{"id":1385001,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B redeemable convertible preferred stock","published_at":"2024-10-17T20:19:30.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":197456,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP\") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited (\"Advisors II\") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors II may be deemed to have voting and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. Advisors II exercises voting and investment power through an investment committee comprised of Carl L. Gordon, David P. Bonita, and the Reporting Person, each of whom disclaims beneficial ownership of the securities held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, Advisors II, Israel GP, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, Advisors II, Israel GP, OrbiMed Advisors, or GP VIII is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":197456},"source":{"system":"sec-edgar","filing":"0000947871-24-000807","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2022626/000094787124000807/ownership.xml","form_type":"4"}},{"id":1385000,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A redeemable convertible preferred stock","published_at":"2024-10-17T20:19:30.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":2098000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, Advisors II, Israel GP, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, Advisors II, Israel GP, OrbiMed Advisors, or GP VIII is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2098000},"source":{"system":"sec-edgar","filing":"0000947871-24-000807","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2022626/000094787124000807/ownership.xml","form_type":"4"}},{"id":1384999,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A redeemable convertible preferred stock","published_at":"2024-10-17T20:19:30.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":524500,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP\") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited (\"Advisors II\") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors II may be deemed to have voting and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. Advisors II exercises voting and investment power through an investment committee comprised of Carl L. Gordon, David P. Bonita, and the Reporting Person, each of whom disclaims beneficial ownership of the securities held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, Advisors II, Israel GP, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, Advisors II, Israel GP, OrbiMed Advisors, or GP VIII is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":524500},"source":{"system":"sec-edgar","filing":"0000947871-24-000807","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2022626/000094787124000807/ownership.xml","form_type":"4"}},{"id":1384998,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T20:19:30.000Z","date":"2024-10-15","kind":"purchase","planned":false,"acquired":true,"shares":660000,"price":17,"value":11220000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, Advisors II, Israel GP, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, Advisors II, Israel GP, OrbiMed Advisors, or GP VIII is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":4554873,"source":{"system":"sec-edgar","filing":"0000947871-24-000807","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2022626/000094787124000807/ownership.xml","form_type":"4"}},{"id":1384997,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T20:19:30.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":2887833,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, Advisors II, Israel GP, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, Advisors II, Israel GP, OrbiMed Advisors, or GP VIII is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3894873,"source":{"system":"sec-edgar","filing":"0000947871-24-000807","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2022626/000094787124000807/ownership.xml","form_type":"4"}},{"id":1384996,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T20:19:30.000Z","date":"2024-10-15","kind":"purchase","planned":false,"acquired":true,"shares":165000,"price":17,"value":2805000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP\") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited (\"Advisors II\") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors II may be deemed to have voting and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. Advisors II exercises voting and investment power through an investment committee comprised of Carl L. Gordon, David P. Bonita, and the Reporting Person, each of whom disclaims beneficial ownership of the securities held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, Advisors II, Israel GP, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, Advisors II, Israel GP, OrbiMed Advisors, or GP VIII is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1138716,"source":{"system":"sec-edgar","filing":"0000947871-24-000807","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2022626/000094787124000807/ownership.xml","form_type":"4"}},{"id":1384995,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T20:19:30.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":721956,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP\") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited (\"Advisors II\") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors II may be deemed to have voting and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. Advisors II exercises voting and investment power through an investment committee comprised of Carl L. Gordon, David P. Bonita, and the Reporting Person, each of whom disclaims beneficial ownership of the securities held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, Advisors II, Israel GP, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, Advisors II, Israel GP, OrbiMed Advisors, or GP VIII is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":973716,"source":{"system":"sec-edgar","filing":"0000947871-24-000807","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022626/000094787124000807/ownership.xml","form_type":"4"}},{"id":1386804,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-15T20:15:11.000Z","date":"2024-10-10","kind":"grant","planned":false,"acquired":true,"shares":17096,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest upon the earlier of (i) October 10, 2025, and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to an agreement with OrbiMed Advisors LLC, OrbiMed Capital GP VIII LLC, OrbiMed Israel GP II, L.P., and OrbiMed Advisors Israel II Limited, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC, OrbiMed Capital GP VIII LLC, OrbiMed Israel GP II, L.P., and OrbiMed Advisors Israel II Limited, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VIII, LP and OrbiMed Israel Partners II, L.P."}],"balance_after":17096,"derivative":{"exercise_price":17,"expiration_date":"2034-10-09","underlying":"Common Stock","underlying_shares":17096},"source":{"system":"sec-edgar","filing":"0000950170-24-114685","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022626/000095017024114685/ownership.xml","form_type":"4"}},{"id":1509029,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":1,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":2,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24161,"kind":"person","name":"GORDON CARL L","position":3,"cik":"0001282930","reported_name":"GORDON CARL L","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24622,"kind":"person","name":"Chimovits Erez","position":4,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (Right to Buy)","published_at":"2024-05-20T20:39:38.000Z","date":"2024-05-15","kind":"other","planned":false,"acquired":false,"shares":9280408,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OIP. OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP and OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of OrbiMed Israel, OrbiMed BioFund, Carl L. Gordon, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":0.244,"exercise_date":"2023-05-04","expiration_date":"2033-05-04","underlying":"Common Stock","underlying_shares":9280408},"source":{"system":"sec-edgar","filing":"0000947871-24-000498","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787124000498/ownership.xml","form_type":"4"}},{"id":1509028,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":1,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":2,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24161,"kind":"person","name":"GORDON CARL L","position":3,"cik":"0001282930","reported_name":"GORDON CARL L","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24622,"kind":"person","name":"Chimovits Erez","position":4,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-05-20T20:39:38.000Z","date":"2024-05-15","kind":"sale","planned":false,"acquired":false,"shares":24344,"price":0.3812,"value":9279.9328,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 15, 2024, OrbiMed Israel Partners Limited Partnership (\"OIP\") exercised pre-funded warrants (\"Warrants\") to purchase 9,280,408 shares of the Issuer's common stock for $0.244 per share. OIP paid the exercise price on a cashless basis, resulting in the Issuer withholding 24,344 of the Warrant shares to pay the exercise price and issuing to OIP the remaining 9,256,064 shares. The shares of the Issuer's common stock withheld to pay the exercise price of the Warrants are matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), with a portion of OIP's purchase of certain derivative securities on March 15, 2024. OIP will disgorge to the Issuer the statutory \"profits\" pursuant to Section 16(b) of the Exchange Act that resulted from such transactions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OIP. OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP and OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of OrbiMed Israel, OrbiMed BioFund, Carl L. Gordon, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":13773653,"source":{"system":"sec-edgar","filing":"0000947871-24-000498","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787124000498/ownership.xml","form_type":"4"}},{"id":1509027,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":1,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":2,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24161,"kind":"person","name":"GORDON CARL L","position":3,"cik":"0001282930","reported_name":"GORDON CARL L","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24622,"kind":"person","name":"Chimovits Erez","position":4,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-05-20T20:39:38.000Z","date":"2024-05-15","kind":"other","planned":false,"acquired":true,"shares":9280408,"price":0.244,"value":2264419.552,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OIP. OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP and OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of OrbiMed Israel, OrbiMed BioFund, Carl L. Gordon, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":13797997,"source":{"system":"sec-edgar","filing":"0000947871-24-000498","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787124000498/ownership.xml","form_type":"4"}},{"id":1568878,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":1,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":2,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24161,"kind":"person","name":"GORDON CARL L","position":3,"cik":"0001282930","reported_name":"GORDON CARL L","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24622,"kind":"person","name":"Chimovits Erez","position":4,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (Right to Buy)","published_at":"2024-03-20T01:06:46.000Z","date":"2024-03-15","kind":"purchase","planned":false,"acquired":true,"shares":2163500,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These warrants to purchase shares of the Issuer's common stock were purchased from the Issuer in a private placement. The warrants are exercisable for one share of the Issuer's common stock per warrant at any time following the Stockholder Approval, subject to the Beneficial Ownership Limitation, and expire on the 24-month anniversary of the date on which they are first exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These warrants to purchase shares of the Issuer's common stock were purchased from the Issuer in a private placement. The warrants are exercisable for one share of the Issuer's common stock per warrant at any time following the Stockholder Approval, subject to the Beneficial Ownership Limitation, and expire on the 24-month anniversary of the date on which they are first exercisable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These warrants to purchase shares of the Issuer's common stock were purchased from the Issuer in a private placement. The warrants are exercisable for one share of the Issuer's common stock per warrant at any time following the Stockholder Approval, subject to the Beneficial Ownership Limitation, and expire on the 24-month anniversary of the date on which they are first exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP and OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of OrbiMed Israel, OrbiMed BioFund, Carl L. Gordon, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2163500,"derivative":{"exercise_price":0.2311,"underlying":"Common Stock","underlying_shares":2163500},"source":{"system":"sec-edgar","filing":"0000947871-24-000289","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787124000289/ownership.xml","form_type":"4"}},{"id":1568877,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":1,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":2,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24161,"kind":"person","name":"GORDON CARL L","position":3,"cik":"0001282930","reported_name":"GORDON CARL L","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24622,"kind":"person","name":"Chimovits Erez","position":4,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series X Preferred Stock","published_at":"2024-03-20T01:06:46.000Z","date":"2024-03-15","kind":"purchase","planned":false,"acquired":true,"shares":4327,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These shares of the Issuer's Series X Non-Voting Convertible Preferred Stock (\"Series X Preferred Stock\") were purchased from the Issuer in a private placement. Each share of Series X Preferred Stock is automatically convertible into 1,000 shares of the Issuer's common stock at 5:00 p.m. Eastern time on the fourth business day after the date the Issuer's stockholders approve the conversion of the Series X preferred Stock into shares of the Issuer's common stock (the \"Stockholder Approval\") or at any time at the option of the holder following 5:00 p.m. Eastern time on the third business day after the date the Stockholder Approval is obtained."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The conversion of the Series X Preferred Stock into shares of the Issuer's common stock is subject to an issuance limitation that prohibits the holder from converting the shares of Series X Preferred Stock into shares of the Issuer's common stock to the extent that after giving effect to such issuance after conversion, the holder (together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates, including the Reporting Persons) would beneficially own in excess of 19.9% of the shares of common stock outstanding immediately after giving effect to the issuance of the shares of common stock issued upon conversion of the shares of Series X Preferred Stock (the \"Beneficial Ownership Limitation\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the Issuer's Series X Non-Voting Convertible Preferred Stock (\"Series X Preferred Stock\") were purchased from the Issuer in a private placement. Each share of Series X Preferred Stock is automatically convertible into 1,000 shares of the Issuer's common stock at 5:00 p.m. Eastern time on the fourth business day after the date the Issuer's stockholders approve the conversion of the Series X preferred Stock into shares of the Issuer's common stock (the \"Stockholder Approval\") or at any time at the option of the holder following 5:00 p.m. Eastern time on the third business day after the date the Stockholder Approval is obtained."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The conversion of the Series X Preferred Stock into shares of the Issuer's common stock is subject to an issuance limitation that prohibits the holder from converting the shares of Series X Preferred Stock into shares of the Issuer's common stock to the extent that after giving effect to such issuance after conversion, the holder (together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates, including the Reporting Persons) would beneficially own in excess of 19.9% of the shares of common stock outstanding immediately after giving effect to the issuance of the shares of common stock issued upon conversion of the shares of Series X Preferred Stock (the \"Beneficial Ownership Limitation\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares of the Issuer's Series X Non-Voting Convertible Preferred Stock (\"Series X Preferred Stock\") were purchased from the Issuer in a private placement. Each share of Series X Preferred Stock is automatically convertible into 1,000 shares of the Issuer's common stock at 5:00 p.m. Eastern time on the fourth business day after the date the Issuer's stockholders approve the conversion of the Series X preferred Stock into shares of the Issuer's common stock (the \"Stockholder Approval\") or at any time at the option of the holder following 5:00 p.m. Eastern time on the third business day after the date the Stockholder Approval is obtained."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The conversion of the Series X Preferred Stock into shares of the Issuer's common stock is subject to an issuance limitation that prohibits the holder from converting the shares of Series X Preferred Stock into shares of the Issuer's common stock to the extent that after giving effect to such issuance after conversion, the holder (together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates, including the Reporting Persons) would beneficially own in excess of 19.9% of the shares of common stock outstanding immediately after giving effect to the issuance of the shares of common stock issued upon conversion of the shares of Series X Preferred Stock (the \"Beneficial Ownership Limitation\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These shares of the Issuer's Series X Non-Voting Convertible Preferred Stock (\"Series X Preferred Stock\") were purchased from the Issuer in a private placement. Each share of Series X Preferred Stock is automatically convertible into 1,000 shares of the Issuer's common stock at 5:00 p.m. Eastern time on the fourth business day after the date the Issuer's stockholders approve the conversion of the Series X preferred Stock into shares of the Issuer's common stock (the \"Stockholder Approval\") or at any time at the option of the holder following 5:00 p.m. Eastern time on the third business day after the date the Stockholder Approval is obtained."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The conversion of the Series X Preferred Stock into shares of the Issuer's common stock is subject to an issuance limitation that prohibits the holder from converting the shares of Series X Preferred Stock into shares of the Issuer's common stock to the extent that after giving effect to such issuance after conversion, the holder (together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates, including the Reporting Persons) would beneficially own in excess of 19.9% of the shares of common stock outstanding immediately after giving effect to the issuance of the shares of common stock issued upon conversion of the shares of Series X Preferred Stock (the \"Beneficial Ownership Limitation\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP and OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of OrbiMed Israel, OrbiMed BioFund, Carl L. Gordon, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":4327,"derivative":{"underlying":"Common Stock","underlying_shares":4327000},"source":{"system":"sec-edgar","filing":"0000947871-24-000289","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787124000289/ownership.xml","form_type":"4"}},{"id":1842241,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24622,"kind":"person","name":"Chimovits Erez","position":9,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-29T20:46:01.000Z","date":"2023-06-27","kind":"purchase","planned":false,"acquired":true,"shares":58000,"price":2.09,"value":121220.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.08 to a high of $2.12 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VI and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, GP V, GP VI, Genesis GP, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. OrbiMed Advisors, GP V and GP VI have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":748054,"source":{"system":"sec-edgar","filing":"0000947871-23-000713","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000713/ownership.xml","form_type":"4"}},{"id":1842240,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24622,"kind":"person","name":"Chimovits Erez","position":9,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-29T20:46:01.000Z","date":"2023-06-27","kind":"purchase","planned":false,"acquired":true,"shares":442000,"price":2.09,"value":923780.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.08 to a high of $2.12 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI V and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, GP V, GP VI, Genesis GP, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. OrbiMed Advisors, GP V and GP VI have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":5685259,"source":{"system":"sec-edgar","filing":"0000947871-23-000713","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000713/ownership.xml","form_type":"4"}},{"id":1842239,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24622,"kind":"person","name":"Chimovits Erez","position":9,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-29T20:46:01.000Z","date":"2023-06-27","kind":"purchase","planned":false,"acquired":true,"shares":250000,"price":2.09,"value":522500.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.08 to a high of $2.12 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"OrbiMed Israel GP II\") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited (\"OrbiMed Israel II\") is the general partner of OrbiMed Israel GP II. By virtue of such relationships, OrbiMed Israel GP II and OrbiMed Israel II may be deemed to have voting and investment power over the shares of common stock held by OIP II and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Israel II exercises this investment and voting power through an investment committee comprised of Carl L. Gordon, David Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership over the shares of common stock held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, GP V, GP VI, Genesis GP, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. OrbiMed Advisors, GP V and GP VI have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":646657,"source":{"system":"sec-edgar","filing":"0000947871-23-000713","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000713/ownership.xml","form_type":"4"}},{"id":1842238,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24622,"kind":"person","name":"Chimovits Erez","position":9,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-29T20:46:01.000Z","date":"2023-06-27","kind":"purchase","planned":false,"acquired":true,"shares":125000,"price":2.09,"value":261250.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.08 to a high of $2.12 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel GP\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power over the shares of common stock held by OIP and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Israel GP exercises this investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits, each of whom disclaims beneficial ownership over the shares of common stock held by OIP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, GP V, GP VI, Genesis GP, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. OrbiMed Advisors, GP V and GP VI have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1027885,"source":{"system":"sec-edgar","filing":"0000947871-23-000713","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000713/ownership.xml","form_type":"4"}},{"id":1947120,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":1,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":2,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24161,"kind":"person","name":"GORDON CARL L","position":3,"cik":"0001282930","reported_name":"GORDON CARL L","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24622,"kind":"person","name":"Chimovits Erez","position":4,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (Right to Buy)","published_at":"2023-03-17T20:29:56.000Z","date":"2023-02-27","kind":"purchase","acquired":true,"shares":1789959,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the Issuer's common stock and warrants to purchase shares of the Issuer's common stock were purchased from the Issuer in a private placement. The warrants are exercisable for one share of the Issuer's common stock per warrant, subject to an issuance limitation that prohibits the holder from exercising the warrants to the extent that after giving effect to such issuance after exercise, the holder (together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates, including the Reporting Persons) would beneficially own in excess of 9.99% of the shares of common stock outstanding immediately after giving effect to the issuance of the shares of common stock issuance upon exercise of the warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP and OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of OrbiMed Israel, OrbiMed BioFund, Carl Gordon, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1789959,"derivative":{"exercise_price":0.244,"exercise_date":"2023-02-27","expiration_date":"2033-02-27","underlying":"Common Stock","underlying_shares":1789959},"source":{"system":"sec-edgar","filing":"0000947871-23-000336","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787123000336/ownership.xml","form_type":"4"}},{"id":1947119,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":1,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":2,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24161,"kind":"person","name":"GORDON CARL L","position":3,"cik":"0001282930","reported_name":"GORDON CARL L","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24622,"kind":"person","name":"Chimovits Erez","position":4,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-03-17T20:29:56.000Z","date":"2023-02-27","kind":"purchase","acquired":true,"shares":348000,"price":0.245,"value":85260.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of the Issuer's common stock and warrants to purchase shares of the Issuer's common stock were purchased from the Issuer in a private placement. The warrants are exercisable for one share of the Issuer's common stock per warrant, subject to an issuance limitation that prohibits the holder from exercising the warrants to the extent that after giving effect to such issuance after exercise, the holder (together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates, including the Reporting Persons) would beneficially own in excess of 9.99% of the shares of common stock outstanding immediately after giving effect to the issuance of the shares of common stock issuance upon exercise of the warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP and OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of OrbiMed Israel, OrbiMed BioFund, Carl Gordon, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3161489,"source":{"system":"sec-edgar","filing":"0000947871-23-000336","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787123000336/ownership.xml","form_type":"4"}},{"id":2850459,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-19T02:44:15.000Z","date":"2021-02-12","kind":"grant","acquired":true,"shares":104050,"price":13,"value":1352650.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares of the Issuer's common stock were purchased in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"OrbiMed Israel GP II\") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited (\"OrbiMed Israel II\") is the general partner of OrbiMed Israel GP II. By virtue of such relationships, OrbiMed Israel GP II and OrbiMed Israel II may be deemed to have voting and investment power with respect to the shares held directly by OIP II noted above and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Israel II exercises this investment and voting power through a management committee comprised of the Reporting Person, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of the Reporting Person, OrbiMed Advisors, GP V, GP VI, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II and OrbiMed Israel II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP V, GP VI, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II or OrbiMed Israel II is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":396657,"source":{"system":"sec-edgar","filing":"0000947871-21-000242","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000094787121000242/ownership.xml","form_type":"4"}},{"id":2850458,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-19T02:44:15.000Z","date":"2021-02-12","kind":"grant","acquired":true,"shares":420299,"price":13,"value":5463887.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares of the Issuer's common stock were purchased in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of the Reporting Person, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of the Reporting Person, OrbiMed Advisors, GP V, GP VI, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II and OrbiMed Israel II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP V, GP VI, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II or OrbiMed Israel II is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":5243259,"source":{"system":"sec-edgar","filing":"0000947871-21-000242","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000094787121000242/ownership.xml","form_type":"4"}},{"id":3013446,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-05T21:32:48.000Z","date":"2020-10-01","kind":"purchase","acquired":true,"shares":296296,"price":6,"value":1777776.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\"). OrbiMed Genesis GP (\"Genesis GP\") is the general partner of Genesis Master Fund and Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and Advisors may be deemed to have voting and investment power over the securities held by Genesis Master Fund and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by Genesis Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is the designated representative of OrbiMed Limited on the Issuer's board of directors. Each of Advisors, GP VI, OrbiMed Limited, OrbiMed Israel, Genesis GP, and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":296296,"source":{"system":"sec-edgar","filing":"0000947871-20-000776","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787120000776/ownership.xml","form_type":"4"}},{"id":3013445,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-05T21:32:48.000Z","date":"2020-10-01","kind":"purchase","acquired":true,"shares":639212,"price":6,"value":3835272.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"OrbiMed Israel\") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited (\"OrbiMed Limited\") is the managing member of OrbiMed Israel. By virtue of such relationships, OrbiMed Israel and OrbiMed Limited may be deemed to have voting and investment power over the securities held by OIP II and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan Silverstein, Nissim Darvish, Anat Naschitz, and the Reporting Person, each of whom disclaims beneficial ownership of the Shares held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is the designated representative of OrbiMed Limited on the Issuer's board of directors. Each of Advisors, GP VI, OrbiMed Limited, OrbiMed Israel, Genesis GP, and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":4126972,"source":{"system":"sec-edgar","filing":"0000947871-20-000776","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787120000776/ownership.xml","form_type":"4"}},{"id":3013444,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-05T21:32:48.000Z","date":"2020-10-01","kind":"purchase","acquired":true,"shares":545974,"price":6,"value":3275844.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI and OrbiMed Advisors LLC (\"Advisors\") is the managing member of GP VI. By virtue of such relationships, GP VI and Advisors may be deemed to have voting and investment power over the securities held by OPI VI and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is the designated representative of OrbiMed Limited on the Issuer's board of directors. Each of Advisors, GP VI, OrbiMed Limited, OrbiMed Israel, Genesis GP, and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3524997,"source":{"system":"sec-edgar","filing":"0000947871-20-000776","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787120000776/ownership.xml","form_type":"4"}},{"id":3028659,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-09-18T01:50:45.000Z","date":"2020-09-17","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on September 17, 2020 with respect to 30,000 shares of Common Stock. 1/36th of the shares of the Issuer's common stock subject to the option shall vest on each of the next thirty-six (36) monthly anniversaries of the grant date, provided that the Reporting Person remains in continuous service as of the applicable vesting date. Pursuant to agreements with OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II and OrbiMed Israel II, the Reporting Person is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, and OrbiMed Israel II, which will in turn ensure that such securities or economic benefit are provided to OIP and OIP II."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"This option was granted on September 17, 2020 with respect to 30,000 shares of Common Stock. 1/36th of the shares of the Issuer's common stock subject to the option shall vest on each of the next thirty-six (36) monthly anniversaries of the grant date, provided that the Reporting Person remains in continuous service as of the applicable vesting date. Pursuant to agreements with OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II and OrbiMed Israel II, the Reporting Person is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, and OrbiMed Israel II, which will in turn ensure that such securities or economic benefit are provided to OIP and OIP II."}],"balance_after":30000,"derivative":{"exercise_price":16.11,"expiration_date":"2030-09-17","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000947871-20-000740","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000094787120000740/ownership.xml","form_type":"4"}},{"id":3028658,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-09-18T01:50:45.000Z","date":"2020-09-15","kind":"grant","acquired":true,"shares":292607,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for 2,359,734 shares of the common stock of Old Adicet on the closing of the Merger, as described in footnote 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"OrbiMed Israel GP II\") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited (\"OrbiMed Israel II\") is the general partner of OrbiMed Israel GP II. By virtue of such relationships, OrbiMed Israel GP II and OrbiMed Israel II may be deemed to have voting and investment power with respect to the shares held directly by OIP II noted above and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Israel II exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and the Reporting Person, each of whom disclaims beneficial ownership of the shares held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, and OrbiMed Israel II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, or OrbiMed Israel II is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":292607,"source":{"system":"sec-edgar","filing":"0000947871-20-000740","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000094787120000740/ownership.xml","form_type":"4"}},{"id":3028657,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-09-18T01:50:45.000Z","date":"2020-09-15","kind":"grant","acquired":true,"shares":902885,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 7,281,335 shares of the common stock of Adicet Bio, Inc., (\"Old Adicet\") on the closing of the merger (the \"Merger\") pursuant to the Agreement and Plan of Merger dated April 18, 2020 (the \"Merger Agreement\") by and among the Issuer, Old Adicet and Project Oasis Merger Sub, Inc., a direct, wholly-owned subsidiary of the Issuer, whereby each share of Old Adicet common stock was canceled and automatically converted into .1240 shares of Issuer common stock (the \"Exchange Ratio\"), with fractional shares being eliminated after first being aggregated, as provided in the Merger Agreement. The Issuer was renamed Adicet Bio, Inc. following the closing of the Merger."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel GP\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power with respect to the shares held directly by OIP noted above and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Israel GP exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and the Reporting Person, each of whom disclaims beneficial ownership of the shares held by OIP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, and OrbiMed Israel II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, or OrbiMed Israel II is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":902855,"source":{"system":"sec-edgar","filing":"0000947871-20-000740","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000094787120000740/ownership.xml","form_type":"4"}},{"id":3102020,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-24T00:00:23.000Z","date":"2020-06-19","kind":"grant","acquired":true,"shares":2513,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the RSUs will vest on January 1, 2021, subject to the terms and conditions of the award and the Company's 2018 Plan."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"All of the RSUs will vest on January 1, 2021, subject to the terms and conditions of the award and the Company's 2018 Plan."}],"balance_after":2513,"derivative":{"underlying":"Common Stock","underlying_shares":2513},"source":{"system":"sec-edgar","filing":"0001209191-20-038665","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000120919120038665/doc4.xml","form_type":"4"}},{"id":3102019,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-24T00:00:23.000Z","date":"2020-06-19","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All of the options will vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of LogicBio Therapeutics, Inc. (the \"Company\") 2021 Annual Meeting of Stockholders, subject to the terms and conditions of the award and the Company's 2018 Equity Incentive Plan (the \"2018 Plan\")."}],"balance_after":10000,"derivative":{"exercise_price":7.96,"expiration_date":"2030-06-19","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-038665","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000120919120038665/doc4.xml","form_type":"4"}},{"id":3193290,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Options - Right to Buy","published_at":"2020-03-27T20:04:11.000Z","date":"2020-03-25","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 25, 2021, and the remainder vesting in 12 equal quarterly installments over three years."}],"balance_after":16000,"derivative":{"exercise_price":6.21,"expiration_date":"2030-03-25","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001213900-20-007671","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000121390020007671/ownership.xml","form_type":"4"}},{"id":3249563,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2020-02-25T22:11:54.000Z","date":"2020-01-14","kind":"sale","acquired":true,"shares":646204,"price":0.2,"value":129240.8,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Warrants (\"Warrants\") to purchase shares of the Issuer's common stock (\"Shares\"). The Warrants are immediately exercisable and have an exercise price of $4.00 per Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is the designated representative of OrbiMed Israel GP Ltd. on the Issuer's Board of Directors. The reportable securities are owned directly by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed BioFund. The Reporting Person disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"exercise_date":"2019-05-02","expiration_date":"2024-05-02","underlying":"Common Stock","underlying_shares":646204},"source":{"system":"sec-edgar","filing":"0000947871-20-000145","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787120000145/ownership.xml","form_type":"4"}},{"id":3249562,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2020-02-25T22:11:54.000Z","date":"2020-01-14","kind":"sale","acquired":true,"shares":646204,"price":0.2,"value":129240.8,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Warrants (\"Warrants\") to purchase shares of the Issuer's common stock (\"Shares\"). The Warrants are immediately exercisable and have an exercise price of $4.00 per Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is the designated representative of OrbiMed Israel GP Ltd. on the Issuer's Board of Directors. The reportable securities are owned directly by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed BioFund. The Reporting Person disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"exercise_date":"2019-05-02","expiration_date":"2020-11-02","underlying":"Common Stock","underlying_shares":646204},"source":{"system":"sec-edgar","filing":"0000947871-20-000145","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787120000145/ownership.xml","form_type":"4"}},{"id":3333979,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-12-21T01:00:15.000Z","date":"2019-12-19","kind":"grant","acquired":true,"shares":10869,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% vests on the earlier of 7/15/2020 or the 2020 Annual Meeting of Stockholders."}],"balance_after":10869,"derivative":{"exercise_price":12.65,"expiration_date":"2029-12-19","underlying":"Common Stock","underlying_shares":10869},"source":{"system":"sec-edgar","filing":"0001209191-19-061662","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000120919119061662/doc4.xml","form_type":"4"}},{"id":3333981,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2019-12-20T18:56:32.000Z","date":"2019-12-19","kind":"purchase","acquired":true,"shares":3500,"price":8.9,"value":31150.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The purchases reported on this Form 4 were made by OrbiMed Israel Partners Limited Partnership (\"OIP LP\"). Following the transactions reported on this Form 4, OIP LP is the direct owner of 1,672,150 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership (\"OII LP\") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\"), which is the general partner of each of OIP LP and OII LP. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP LP and OII LP noted above and, as a result, may be deemed to have beneficial ownership over such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that Mr. Chimovits is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2313489,"source":{"system":"sec-edgar","filing":"0000947871-19-000982","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787119000982/ownership.xml","form_type":"4"}},{"id":3333980,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2019-12-20T18:56:32.000Z","date":"2019-12-18","kind":"purchase","acquired":true,"shares":500,"price":8.93,"value":4465.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The purchases reported on this Form 4 were made by OrbiMed Israel Partners Limited Partnership (\"OIP LP\"). Following the transactions reported on this Form 4, OIP LP is the direct owner of 1,672,150 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership (\"OII LP\") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\"), which is the general partner of each of OIP LP and OII LP. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP LP and OII LP noted above and, as a result, may be deemed to have beneficial ownership over such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that Mr. Chimovits is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2309989,"source":{"system":"sec-edgar","filing":"0000947871-19-000982","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787119000982/ownership.xml","form_type":"4"}},{"id":3343752,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2019-12-12T23:54:38.000Z","date":"2019-12-11","kind":"purchase","acquired":true,"shares":5400,"price":8.92,"value":48168.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The purchases reported on this Form 4 were made by OrbiMed Israel Partners Limited Partnership (\"OIP LP\"). Following the transactions reported on this Form 4, OIP LP is the direct owner of 1,668,150 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership (\"OII LP\") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\"), which is the general partner of each of OIP LP and OII LP. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP LP and OII LP noted above and, as a result, may be deemed to have beneficial ownership over such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that Mr. Chimovits is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2309489,"source":{"system":"sec-edgar","filing":"0000947871-19-000962","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787119000962/ownership.xml","form_type":"4"}},{"id":3343751,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2019-12-12T23:54:38.000Z","date":"2019-12-10","kind":"purchase","acquired":true,"shares":3400,"price":8.75,"value":29750.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The purchases reported on this Form 4 were made by OrbiMed Israel Partners Limited Partnership (\"OIP LP\"). Following the transactions reported on this Form 4, OIP LP is the direct owner of 1,668,150 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership (\"OII LP\") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\"), which is the general partner of each of OIP LP and OII LP. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP LP and OII LP noted above and, as a result, may be deemed to have beneficial ownership over such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that Mr. Chimovits is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2304089,"source":{"system":"sec-edgar","filing":"0000947871-19-000962","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787119000962/ownership.xml","form_type":"4"}},{"id":3348265,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2019-12-10T01:19:20.000Z","date":"2019-12-09","kind":"purchase","acquired":true,"shares":6000,"price":8.68,"value":52080.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects a decrease of one share to account for rounding of fractional shares initially reported on the Reporting Person's Form 3."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The purchases reported on this Form 4 were made by OrbiMed Israel Partners Limited Partnership (\"OIP LP\"). Following the transactions reported on this Form 4, OIP LP is the direct owner of 1,659,350 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership (\"OII LP\") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\"), which is the general partner of each of OIP LP and OII LP. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP LP and OII LP noted above and, as a result, may be deemed to have beneficial ownership over such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that Mr. Chimovits is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2300689,"source":{"system":"sec-edgar","filing":"0000947871-19-000947","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787119000947/ownership.xml","form_type":"4"}},{"id":3348264,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2019-12-10T01:19:20.000Z","date":"2019-12-06","kind":"purchase","acquired":true,"shares":800,"price":8,"value":6400.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects a decrease of one share to account for rounding of fractional shares initially reported on the Reporting Person's Form 3."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The purchases reported on this Form 4 were made by OrbiMed Israel Partners Limited Partnership (\"OIP LP\"). Following the transactions reported on this Form 4, OIP LP is the direct owner of 1,659,350 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership (\"OII LP\") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\"), which is the general partner of each of OIP LP and OII LP. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP LP and OII LP noted above and, as a result, may be deemed to have beneficial ownership over such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that Mr. Chimovits is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2294689,"source":{"system":"sec-edgar","filing":"0000947871-19-000947","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787119000947/ownership.xml","form_type":"4"}},{"id":3348263,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2019-12-10T01:19:20.000Z","date":"2019-12-05","kind":"purchase","acquired":true,"shares":3400,"price":7.99,"value":27166.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects a decrease of one share to account for rounding of fractional shares initially reported on the Reporting Person's Form 3."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The purchases reported on this Form 4 were made by OrbiMed Israel Partners Limited Partnership (\"OIP LP\"). Following the transactions reported on this Form 4, OIP LP is the direct owner of 1,659,350 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership (\"OII LP\") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\"), which is the general partner of each of OIP LP and OII LP. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP LP and OII LP noted above and, as a result, may be deemed to have beneficial ownership over such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that Mr. Chimovits is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2293889,"source":{"system":"sec-edgar","filing":"0000947871-19-000947","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787119000947/ownership.xml","form_type":"4"}},{"id":3461963,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-15T20:05:36.000Z","date":"2019-07-11","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20000,"derivative":{"exercise_price":0.88,"exercise_date":"2020-07-11","expiration_date":"2029-07-11","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-19-019599","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000089924319019599/doc4.xml","form_type":"4"}},{"id":3538136,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2019-05-06T21:28:18.000Z","date":"2019-05-02","kind":"purchase","acquired":true,"shares":646204,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Warrants (\"Warrants\") to purchase shares of the Issuer's common stock (\"Shares\"). The Warrants are immediately exercisable and have an exercise price of $4.00 per Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Warrants (\"Warrants\") to purchase shares of the Issuer's common stock (\"Shares\"). The Warrants are immediately exercisable and have an exercise price of $4.00 per Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is the designated representative of OrbiMed Israel GP Ltd. on the Issuer's Board of Directors. The reportable securities are owned directly by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed BioFund. The Reporting Person disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any."}],"balance_after":646204,"derivative":{"exercise_date":"2019-05-02","expiration_date":"2024-05-02","underlying":"Common Stock","underlying_shares":646204},"source":{"system":"sec-edgar","filing":"0000947871-19-000336","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787119000336/ownership.xml","form_type":"4"}},{"id":3538135,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2019-05-06T21:28:18.000Z","date":"2019-05-02","kind":"purchase","acquired":true,"shares":646204,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Warrants (\"Warrants\") to purchase shares of the Issuer's common stock (\"Shares\"). The Warrants are immediately exercisable and have an exercise price of $4.00 per Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Warrants (\"Warrants\") to purchase shares of the Issuer's common stock (\"Shares\"). The Warrants are immediately exercisable and have an exercise price of $4.00 per Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is the designated representative of OrbiMed Israel GP Ltd. on the Issuer's Board of Directors. The reportable securities are owned directly by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed BioFund. The Reporting Person disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any."}],"balance_after":646204,"derivative":{"exercise_date":"2019-05-02","expiration_date":"2020-11-02","underlying":"Common Stock","underlying_shares":646204},"source":{"system":"sec-edgar","filing":"0000947871-19-000336","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787119000336/ownership.xml","form_type":"4"}},{"id":3538134,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-06T21:28:18.000Z","date":"2019-05-02","kind":"purchase","acquired":true,"shares":646204,"price":3.1,"value":2003232.4,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is the designated representative of OrbiMed Israel GP Ltd. on the Issuer's Board of Directors. The reportable securities are owned directly by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed BioFund. The Reporting Person disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any."}],"balance_after":3183314,"source":{"system":"sec-edgar","filing":"0000947871-19-000336","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787119000336/ownership.xml","form_type":"4"}},{"id":3783040,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2018-10-25T22:24:35.000Z","date":"2018-10-23","kind":"exercise","acquired":false,"shares":3046943,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Upon closing of the Issuer's initial public offering, each share of Series A and Series B Convertible Preferred Stock automatically converted into 0.5235794 shares of Common Stock without payment or further consideration. There was no expiration date for the Series A or Series B Convertible Preferred Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon closing of the Issuer's initial public offering, each share of Series A and Series B Convertible Preferred Stock automatically converted into 0.5235794 shares of Common Stock without payment or further consideration. There was no expiration date for the Series A or Series B Convertible Preferred Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Upon closing of the Issuer's initial public offering, each share of Series A and Series B Convertible Preferred Stock automatically converted into 0.5235794 shares of Common Stock without payment or further consideration. There was no expiration date for the Series A or Series B Convertible Preferred Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is an employee of OrbiMed Advisors Israel II Limited (\"OrbiMed Limited\"), which is the managing member of OrbiMed Israel GP II, L.P. (\"OIP GP\"). OIP GP is the general partner of OrbiMed Israel Partners II, L.P. (\"OIP II\"), the direct beneficial owner of these securities. By virtue of such relationships, OIP GP and OrbiMed Limited may be deemed to have voting and investment power over the securities held by OIP II. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of these securities in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1595316},"source":{"system":"sec-edgar","filing":"0000899243-18-027475","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000089924318027475/doc4.xml","form_type":"4"}},{"id":3783039,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2018-10-25T22:24:35.000Z","date":"2018-10-23","kind":"exercise","acquired":false,"shares":2678571,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Upon closing of the Issuer's initial public offering, each share of Series A and Series B Convertible Preferred Stock automatically converted into 0.5235794 shares of Common Stock without payment or further consideration. There was no expiration date for the Series A or Series B Convertible Preferred Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon closing of the Issuer's initial public offering, each share of Series A and Series B Convertible Preferred Stock automatically converted into 0.5235794 shares of Common Stock without payment or further consideration. There was no expiration date for the Series A or Series B Convertible Preferred Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Upon closing of the Issuer's initial public offering, each share of Series A and Series B Convertible Preferred Stock automatically converted into 0.5235794 shares of Common Stock without payment or further consideration. There was no expiration date for the Series A or Series B Convertible Preferred Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is an employee of OrbiMed Advisors Israel II Limited (\"OrbiMed Limited\"), which is the managing member of OrbiMed Israel GP II, L.P. (\"OIP GP\"). OIP GP is the general partner of OrbiMed Israel Partners II, L.P. (\"OIP II\"), the direct beneficial owner of these securities. By virtue of such relationships, OIP GP and OrbiMed Limited may be deemed to have voting and investment power over the securities held by OIP II. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of these securities in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1402444},"source":{"system":"sec-edgar","filing":"0000899243-18-027475","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000089924318027475/doc4.xml","form_type":"4"}},{"id":3783038,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-10-25T22:24:35.000Z","date":"2018-10-23","kind":"purchase","acquired":true,"shares":490000,"price":10,"value":4900000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is an employee of OrbiMed Advisors Israel II Limited (\"OrbiMed Limited\"), which is the managing member of OrbiMed Israel GP II, L.P. (\"OIP GP\"). OIP GP is the general partner of OrbiMed Israel Partners II, L.P. (\"OIP II\"), the direct beneficial owner of these securities. By virtue of such relationships, OIP GP and OrbiMed Limited may be deemed to have voting and investment power over the securities held by OIP II. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of these securities in which the Reporting Person has no pecuniary interest."}],"balance_after":3487760,"source":{"system":"sec-edgar","filing":"0000899243-18-027475","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000089924318027475/doc4.xml","form_type":"4"}},{"id":3783037,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-10-25T22:24:35.000Z","date":"2018-10-23","kind":"exercise","acquired":true,"shares":2997760,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The total represents shares received upon conversion of Series A and Series B Convertible Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon closing of the Issuer's initial public offering, each share of Series A and Series B Convertible Preferred Stock automatically converted into 0.5235794 shares of Common Stock without payment or further consideration. There was no expiration date for the Series A or Series B Convertible Preferred Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is an employee of OrbiMed Advisors Israel II Limited (\"OrbiMed Limited\"), which is the managing member of OrbiMed Israel GP II, L.P. (\"OIP GP\"). OIP GP is the general partner of OrbiMed Israel Partners II, L.P. (\"OIP II\"), the direct beneficial owner of these securities. By virtue of such relationships, OIP GP and OrbiMed Limited may be deemed to have voting and investment power over the securities held by OIP II. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of these securities in which the Reporting Person has no pecuniary interest."}],"balance_after":2997760,"source":{"system":"sec-edgar","filing":"0000899243-18-027475","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000089924318027475/doc4.xml","form_type":"4"}},{"id":3785903,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":24622,"kind":"person","name":"Chimovits Erez","position":1,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-10-23T01:19:12.000Z","date":"2018-10-18","kind":"grant","acquired":true,"shares":24102,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable in equal installments on each of the first three anniversaries of the grant date, October 18, 2018."}],"balance_after":24102,"derivative":{"exercise_price":10,"expiration_date":"2028-10-17","underlying":"Common Stock","underlying_shares":24102},"source":{"system":"sec-edgar","filing":"0000899243-18-027226","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000089924318027226/doc4.xml","form_type":"4"}}]}